ZA200907909B - VM23 and VM24, two scorpion peptides that block human -t-lymphocyte potassium channels (sub-type KV1.3) with high selectivity and decrease the in vivo DTH-responses in rats - Google Patents
VM23 and VM24, two scorpion peptides that block human -t-lymphocyte potassium channels (sub-type KV1.3) with high selectivity and decrease the in vivo DTH-responses in ratsInfo
- Publication number
- ZA200907909B ZA200907909B ZA200907909A ZA200907909A ZA200907909B ZA 200907909 B ZA200907909 B ZA 200907909B ZA 200907909 A ZA200907909 A ZA 200907909A ZA 200907909 A ZA200907909 A ZA 200907909A ZA 200907909 B ZA200907909 B ZA 200907909B
- Authority
- ZA
- South Africa
- Prior art keywords
- potassium channels
- peptides
- rats
- responses
- sub
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 241000700159 Rattus Species 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title abstract 2
- 102000004257 Potassium Channel Human genes 0.000 title 1
- 241000239226 Scorpiones Species 0.000 title 1
- 108020001213 potassium channel Proteins 0.000 title 1
- 230000001900 immune effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000239282 Centruroides suffusus Species 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 abstract 1
- 108010027296 Kv1.3 Potassium Channel Proteins 0.000 abstract 1
- 102000018706 Kv1.3 Potassium Channel Human genes 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 241000567851 Vaejovis smithi Species 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 150000002611 lead compounds Chemical class 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000004252 protein component Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000002435 venom Substances 0.000 abstract 1
- 210000001048 venom Anatomy 0.000 abstract 1
- 231100000611 venom Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2007/001544 WO2008139243A1 (en) | 2007-05-14 | 2007-05-14 | Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200907909B true ZA200907909B (en) | 2010-07-28 |
Family
ID=38882810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200907909A ZA200907909B (en) | 2007-05-14 | 2009-11-11 | VM23 and VM24, two scorpion peptides that block human -t-lymphocyte potassium channels (sub-type KV1.3) with high selectivity and decrease the in vivo DTH-responses in rats |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8394770B2 (es) |
| EP (1) | EP2158213B1 (es) |
| JP (1) | JP5249319B2 (es) |
| KR (1) | KR101524517B1 (es) |
| CN (1) | CN101796069B (es) |
| AT (1) | ATE537185T1 (es) |
| AU (1) | AU2007353147B2 (es) |
| BR (1) | BRPI0721664A8 (es) |
| CA (1) | CA2686216C (es) |
| DK (1) | DK2158213T3 (es) |
| EA (1) | EA020131B1 (es) |
| ES (1) | ES2379500T3 (es) |
| IL (1) | IL202113A (es) |
| MX (1) | MX2009012092A (es) |
| PT (1) | PT2158213E (es) |
| WO (1) | WO2008139243A1 (es) |
| ZA (1) | ZA200907909B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1931806B1 (en) | 2005-10-07 | 2011-10-05 | California Institute Of Technology | Pkr activation via hybridization chain reaction |
| EP2155770B1 (en) | 2007-05-16 | 2013-10-16 | California Institute of Technology | A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways |
| WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
| US8962241B2 (en) * | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
| US9834439B2 (en) | 2010-07-20 | 2017-12-05 | California Institute Of Technology | Biomolecular self-assembly |
| US8924325B1 (en) * | 2011-02-08 | 2014-12-30 | Lockheed Martin Corporation | Computerized target hostility determination and countermeasure |
| US9856472B2 (en) | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
| GB201408135D0 (en) * | 2014-05-08 | 2014-06-25 | Conogenetix Biosciences Gmbh | Kv1.3 potassium channel antagonists |
| US10246496B2 (en) * | 2014-08-15 | 2019-04-02 | La Trobe University | Potassium channel blockers and use thereof in the treatment of autoimmune diseases |
| EP3481843B1 (en) | 2016-07-05 | 2022-01-26 | California Institute of Technology | Fractional initiator hybridization chain reaction |
| EP3507296B1 (en) | 2016-08-30 | 2022-10-12 | California Institute of Technology | Immunohistochemistry via hybridization chain reaction |
| CN110357950B (zh) * | 2019-07-29 | 2023-04-25 | 武汉大学 | 酸性氨基酸扫描法设计的免疫抑制多肽及应用 |
| EP4284925A1 (en) | 2021-01-26 | 2023-12-06 | California Institute of Technology | Allosteric conditional guide rnas for cell-selective regulation of crispr/cas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494895A (en) * | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
| US6689749B1 (en) * | 1996-12-19 | 2004-02-10 | Suntory Limited | Neuropeptides originating in scorpion |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
-
2007
- 2007-05-14 WO PCT/IB2007/001544 patent/WO2008139243A1/en active Application Filing
- 2007-05-14 EP EP07734817A patent/EP2158213B1/en active Active
- 2007-05-14 PT PT07734817T patent/PT2158213E/pt unknown
- 2007-05-14 US US12/599,978 patent/US8394770B2/en active Active
- 2007-05-14 JP JP2010507993A patent/JP5249319B2/ja active Active
- 2007-05-14 CN CN200780053305.7A patent/CN101796069B/zh active Active
- 2007-05-14 MX MX2009012092A patent/MX2009012092A/es active IP Right Grant
- 2007-05-14 DK DK07734817.5T patent/DK2158213T3/da active
- 2007-05-14 AT AT07734817T patent/ATE537185T1/de active
- 2007-05-14 ES ES07734817T patent/ES2379500T3/es active Active
- 2007-05-14 BR BRPI0721664A patent/BRPI0721664A8/pt not_active Application Discontinuation
- 2007-05-14 CA CA2686216A patent/CA2686216C/en active Active
- 2007-05-14 KR KR1020097026000A patent/KR101524517B1/ko active IP Right Grant
- 2007-05-14 EA EA200901530A patent/EA020131B1/ru unknown
- 2007-05-14 AU AU2007353147A patent/AU2007353147B2/en active Active
-
2009
- 2009-11-11 ZA ZA200907909A patent/ZA200907909B/xx unknown
- 2009-11-12 IL IL202113A patent/IL202113A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2158213A1 (en) | 2010-03-03 |
| AU2007353147B2 (en) | 2014-04-03 |
| BRPI0721664A8 (pt) | 2019-01-22 |
| CN101796069A (zh) | 2010-08-04 |
| EA020131B1 (ru) | 2014-08-29 |
| ES2379500T3 (es) | 2012-04-26 |
| MX2009012092A (es) | 2010-02-12 |
| EA200901530A1 (ru) | 2011-08-30 |
| JP2010528988A (ja) | 2010-08-26 |
| US8394770B2 (en) | 2013-03-12 |
| BRPI0721664A2 (pt) | 2013-01-22 |
| CA2686216A1 (en) | 2008-11-20 |
| WO2008139243A1 (en) | 2008-11-20 |
| KR20100023867A (ko) | 2010-03-04 |
| EP2158213B1 (en) | 2011-12-14 |
| IL202113A0 (en) | 2010-06-16 |
| JP5249319B2 (ja) | 2013-07-31 |
| CA2686216C (en) | 2016-04-12 |
| PT2158213E (pt) | 2012-03-27 |
| DK2158213T3 (da) | 2012-04-10 |
| CN101796069B (zh) | 2014-02-19 |
| IL202113A (en) | 2013-01-31 |
| KR101524517B1 (ko) | 2015-06-10 |
| US20110059064A1 (en) | 2011-03-10 |
| ATE537185T1 (de) | 2011-12-15 |
| AU2007353147A1 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200907909B (en) | VM23 and VM24, two scorpion peptides that block human -t-lymphocyte potassium channels (sub-type KV1.3) with high selectivity and decrease the in vivo DTH-responses in rats | |
| Konno et al. | Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus | |
| WO2004066932A3 (en) | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | |
| BRPI0413276A (pt) | derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente | |
| JP2017537893A5 (es) | ||
| BRPI0511982A (pt) | compostos antiviróticos heterocìclicos | |
| PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
| BRPI0207700B8 (pt) | mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero | |
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| RU2016130108A (ru) | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью | |
| ATE192037T1 (de) | Verwendung von arginin als immunstimulator | |
| AU2021205415A8 (en) | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists | |
| BRPI0409928A (pt) | compostos, enantiÈmeros, composição farmacêutica, uso de compostos, processo para a fabricação de compostos, e, modificação dos processos | |
| CN113816990A (zh) | 修饰的氨基酸及其在adc中的应用 | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| HUP9901411A2 (hu) | Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása | |
| AR045765A1 (es) | Moleculas de union a cd45 y uso terapeutico | |
| BR0012478A (pt) | Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos | |
| BR112018008117A2 (pt) | peptídeo cíclico, suporte para cromatografia de afinidade, anticorpo marcado, conjugado fármaco-anticorpo e preparado farmacêutico | |
| BRPI0511305A (pt) | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 | |
| CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
| BR112019002655A2 (pt) | composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora | |
| BR0316599A (pt) | Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional | |
| AU2003217467B2 (en) | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |